SavedAdd your journal

Journals / Bağcılar Tıp Bülteni / 2022 / Cilt: 7 - Sayı: 2

Predictive Factors of Complete Tumor Response to First Line Chemotherapy in Patients with Extensive-stage Small Cell Lung Cancer

Yaygın Evreli Küçük Hücreli Akciğer Kanseri Tanılı Hastalarda İlk Kemoterapiye Tam Yanıtı Etkileyen Faktörler

Eyyüp ÇAVDAR
Yakup İRİAĞAÇ
Erdoğan Selçuk ŞEBER
Abdullah SAKİN
Pages
130–136
Publication Date
2022-10-12
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

On univariate analysis, predictors for CR to treatment were the absence of brain metastasis, receiving 6 chemotherapy cycles and good performance status (p

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Objective: We aimed to investigate the factors affecting the complete response (CR) rate and the effect of treatment response on survival in patients with extensive stage-small cell lung cancer (ES-SCLC) who received a combination of cisplatin and etoposide as first-line therapy.
📊
Key Findings & Data:Method: This retrospective analysis included 140 ES-SCLC patients, who were followed in an oncology clinic.
💡
Conclusion & Impact:On univariate analysis, predictors for CR to treatment were the absence of brain metastasis, receiving 6 chemotherapy cycles and good performance status (p
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:Domain Parameters

Abstract

Objective: We aimed to investigate the factors affecting the complete response (CR) rate and the effect of treatment response on survival in patients with extensive stage-small cell lung cancer (ES-SCLC) who received a combination of cisplatin and etoposide as first-line therapy. Method: This retrospective analysis included 140 ES-SCLC patients, who were followed in an oncology clinic. Patients were divided into two groups as CR and non-CR according to radiological evaluation after first line chemotherapy. Clinical and demographic characteristics and pretreatment hemogram parameters were obtained from electronic medical record system. Results: While CR was seen in 34 (24.3%) of all patients after the first line chemotherapy, 106 (75.7%) patients were in the non-CR group. On univariate analysis, predictors for CR to treatment were the absence of brain metastasis, receiving 6 chemotherapy cycles and good performance status (p

Özet

Amaç: Yaygın evre-küçük hücreli akciğer kanseri (ES-SCLC) tanılı olup, ilk basamakta sisplatin ve etoposid kombinasyon kemoterapisi alan hastalarda tedaviye tam yanıtı (CR) etkileyen faktörleri ve tedaviye yanıt düzeyinin sağkalıma etkisini araştırdık. Yöntem: Bu retrospektif çalışmada ES-SCLC tanılı 140 hasta incelendi. İlk basamak kemoterapi sonrası radyolojik yanıt değerlendirmesine göre CR ve CR olmayan (non-CR) olarak iki grup belirlendi. Klinik, demografik hasta özellikleri ve tedavi öncesi hemogram parametreleri arşivden elde edildi. Bulgular: Hastaların 34’ü (%24,3) CR, 106 (%75,7) hasta non-CR grubunda yer aldı. Yapılan tek değişkenli analizde tanı anında beyin metastazı yokluğu, 6 kemoterapi siklusu alma ve iyi performans durumu CR için öngörücü faktörler olarak bulundu (sırasıyla p

🔖

Cite This Article

ÇAVDAR, E., İRİAĞAÇ, Y., ŞEBER, E. S., SAKİN, A. (2022). Predictive Factors of Complete Tumor Response to First Line Chemotherapy in Patients with Extensive-stage Small Cell Lung Cancer. Bağcılar Tıp Bülteni, Cilt: 7 - Sayı: 2, 130–136. https://ajindex.com/articles/458873

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (13)

  1. Siegel RL, Miller KD, Fuchs HE, Jemal A. Cancer Statistics, 2021. CA Cancer J Clin 2021;71(1):7-33
  2. Dingemans AC, Früh M, Ardizzoni A, Besse B, Faivre-Finn C, Hendriks LE, et al. Small-cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 2021;32(7):839-853
  3. Owonikoko TK, Dahlberg SE, Khan SA, Gerber DE, Dowell J, Moss RA, et al. A phase 1 safety study of veliparib combined with cisplatin and etoposide in extensive stage small cell lung cancer: A trial of the ECOG-ACRIN Cancer Research Group (E2511). Lung Cancer 2015;89(1):66-70
  4. Zimmerman S, Das A, Wang S, Julian R, Gandhi L, Wolf J. 2017-2018 Scientific Advances in Thoracic Oncology: Small Cell Lung Cancer. J Thorac Oncol 2019;14(5):768-783
  5. Rossi A, Di Maio M, Chiodini P, Rudd RM, Okamoto H, Skarlos DV, et al. Carboplatin- or cisplatin-based chemotherapy in first-line treatment of small-cell lung cancer: The COCIS meta-analysis of individual patient data. J Clin Oncol 2012;30(14):1692-1698
  6. Farago AF, Keane FK. Current standards for clinical management of small cell lung cancer. Transl Lung Cancer Res 2018;7(1):69-79
  7. Demedts IK, Vermaelen KY, Van Meerbeeck JP. Treatment of extensive-stage small cell lung carcinoma: current status and future prospects. Eur Respir J 2010;35(1):202-215
  8. Socinski MA, Weissman C, Hart LL, Beck JT, Choksi JK, Hanson JP, et al. Randomized phase II trial of pemetrexed combined with either cisplatin or carboplatin in untreated extensive-stage smallcell lung cancer. J Clin Oncol 2006;24(30):4840-4847
  9. Foster NR, Qi Y, Shi Q, Krook JE, Kugler JW, Jett JR, et al. Tumor response and progression-free survival as potential surrogate endpoints for overall survival in extensive stage small-cell lung cancer. Cancer 2011;117(6):1262-1271
  10. Ventola CL. Cancer Immunotherapy, Part 3: Challenges and Future Trends. P T 2017;42(8):514-521
  11. Rudin CM, Ismaila N, Hann CL, Malhotra N, Movsas B, Norris K, et al. Treatment of Small-Cell Lung Cancer: American Society of Clinical Oncology Endorsement of the American College of Chest Physicians Guideline. J Clin Oncol 2015;33(34):4106-4111
  12. Kalemkerian GP, Loo BW, Akerley W, Attia A, Bassetti M, Boumber Y, et al. NCCN Guidelines Insights: Small Cell Lung Cancer, Version 2.2018. J Natl Compr Canc Netw 2018;16(10):1171-1182
  13. Ihde DC, Mulshine JL, Kramer BS, Steinberg SM, Linnoila RI, Gazdar AF, et al. Prospective randomized comparison of highdose and standard-dose e